No consensus has been reached on the ideal therapeutic algorithm for myasthenia gravis
(MG). Most patients with MG require induction therapy with high doses of corticosteroids and …

Myasthenia gravis (MG) is the prototypical autoimmune disorder caused by specific
autoantibodies at the neuromuscular junction. Broad-based immunotherapies, such as …

Myasthenia gravis (MG) is an autoantibody-mediated disease that compromises the
acetylcholine receptors or associated structures of the postsynaptic membrane of the …

Progress in the therapy of myasthenia gravis: getting closer... : Current Opinion in Neurology
Progress in the therapy of myasthenia gravis: getting closer to effective targeted …

Myasthenia gravis (MG) is a rare, chronic autoimmune disease with symptoms of fluctuating
muscular weakness and fatigability. The aim of this retrospective cohort study was to …

Therapies for myasthenia gravis (MG) include symptomatic and immunosuppressive/
immunomodulatory treatment. Options for immunosuppression include corticosteroids …

Myasthenia gravis is a well-treatable disease, in which a prompt diagnosis and an adequate
management can achieve satisfactory control of symptoms in the great majority of patients …

Background and purpose Long‐term treatment of myasthenia gravis (MG) includes
symptomatic and course‐modifying therapies that target the immune system. Recently, both …

Abstract The Myasthenia Gravis Activities of Living (MG‐ADL) scale is an 8‐item patient‐
reported scale that measures myasthenia gravis (MG) symptoms and functional status. The …

Myasthenia gravis (MG), a rare disease, is the most common neuromuscular junction
problem. It's the quintessential autoimmune disease with ocular, bulbar, respiratory, axial …